Aerovate Therapeutics, Inc. (AVTE) Misses Q3 EPS by 2c

Aerovate Therapeutics, Inc. (NASDAQ: AVTE) reported Q3 EPS of ($0.71), $0.02 worse than the analyst estimate of ($0.69).

For earnings history and earnings-related data on Aerovate Therapeutics, Inc. (AVTE) click here.

You May Also Be Interested In

• Is Treasury selloff a major issue for stock market bulls?
• BofA Securities Reiterates Buy Rating on Micron Technology (MU); Sees $230+ in EPS by FY30
• The LGL Group (LGL) Misses Q2 EPS by 8c